Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03518320
Title Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Taris Biomedical LLC

bladder urothelial carcinoma


Gemcitabine + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.